Trial Profile
A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Stem-cell-therapeutics-ExCellThera (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies
- Focus Adverse reactions; First in man
- 12 Dec 2022 According to a ExCellThera media release, results from retrospective analysis comparing outcomes of patients treated with ECT-001 to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants were presented in an oral session during the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract #665).
- 12 Dec 2022 Findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants published in the ExCellThera Media Release.
- 04 Nov 2022 According to an ExCellThera media release, findings of a matched-controlled real-world analysis comparing outcomes of patients treated with ECT-001 in this trial to cord blood and matched unrelated donor peripheral blood stem cell transplants control cohorts identified from the CIBMTR (Center for International Blood and Marrow Transplant Research) research database has been accepted for oral presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022